Invex Therapeutics Ltd

A$0.09As of Sun 8 Nov 2026, 12:00 UTC
ASX:IXCHealthcare
Country Australia
PE (Fwd) •••
TSR 7Y CAGR (9.75%)
Div yield —
ROE (29.54%)
Biotechnology
Beta (5Y) 0.55
PE TTM —
TSR TTM (21.74%)
Mkt cap A$6.764M
ROIC (20.44%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$0.105
16.53%
276.38%
Hold 6|12|5|7|6
2Q26
3Q26
4Q26
1Q27
Earnings per share$
—
—
—
—
(2.82%)
(1.82%)
(8.39%)
(7.52%)
Revenue$M
0.495
0.508
0.536
0.530
15.38%
12.22%
13.01%
11.23%
Peers (US$4.645M)
Cap (US$)
PE
5.399M
—
Capital
TTM
5Y
10Y
Leveragex
0.757
0.140
0.113
EBIT/Intx
2.222
0.186
0.228
Own earn%
(110.59)
(360.59)
(291.70)
Sh yield%
40.17
39.28
37.30
Owners
Insiders/Inst%
13.03
49.12
Short interest%
4.64
SBC / revenue%
1.40
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
16
Op margin range%
0–3
$1 testx
—
Incr. ROIC%
4